P
Pluri Inc.
PLURCIK 0001158780NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)NevadaFY ends Jun 30
Period
FY 2025
Revenue
$1.34M
Net Income
$-22.58M
Total Assets
$38.68M
Equity
$-6.84M
Shares Out
10.05M
Op. Cash Flow
$-18.21M
Business
Pluri Inc. is a biotechnology company that leverages a proprietary 3D cell expansion platform to develop scalable, cell-based solutions for healthcare, food and agriculture. It offers placenta-derived cell therapy product candidates (PLX cells), an allogeneic MAIT cell immunotherapy platform, CDMO cell manufacturing services (PluriCDMO™), and cultivated food products including cell-cultured coffee, cacao and a B2B cultivated meat platform. Its key business divisions include Cell Therapy (Pluri Health), PluriCDMO™, AgTech (Coffeesai, Kokomodo) and Food Tech (Ever After Foods). Pluri conducts clinical studies and commercial development through collaborations, joint ventures, licensing agreements and global partnerships across the United States, Europe, Israel and other international markets, serving B2B customers, clinical channels and strategic industry partners.
Summary from filing dated 2025-09-17
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Revenues | 1 | 326,000 | 287,000 | 234,000 | — | |
| Cost of revenues | −682,000 | −4,000 | −9,000 | — | — | |
| Gross profit | 654,000 | 322,000 | 278,000 | 234,000 | — | |
| Research and development expenses | −14 | −14 | −17 | — | — | |
| Less: participation by the NIAID, the IIA and Horizon Europe (defined below) | 1 | 1 | — | — | — | |
| Research and development expenses, net | −13 | −12 | −16 | −25 | −31 | |
| General and administrative expenses | −10 | −10 | −12 | −17 | −21 | |
| Operating loss | −22 | −22 | −27 | −42 | −51 | |
| Financial income (expenses), net | −206,000 | 2 | — | — | — | |
| Interest expense | −873,000 | −866,000 | −843,000 | — | — | |
| Total financial income (expenses), net | −1 | 814,000 | −2 | 219,000 | 758,000 | |
| Loss before taxes | −23 | −21 | — | — | — | |
| Tax benefit | 5,000 | — | — | — | — | |
| Net loss | −23 | −21 | −29 | −41 | −50 | |
| Net loss attributed to non-controlling interests | −667,000 | −456,000 | −566,000 | −132,000 | — | |
| Net loss attributed to shareholders | −23 | −21 | −28 | −41 | −50 | |
| Basic loss per share (in Dollars per share) | −3.56 | −3.99 | −6.24 | −1.28 | −1.77 | |
| Diluted loss per share (in Dollars per share) | −3.56 | −3.99 | −6.24 | −1.28 | −1.77 | |
| Weighted average number of shares used in computing basic loss per share (in Shares) | 6 | 5 | 5 | 32 | 28 | |
| Weighted average number of shares used in computing diluted loss per share (in Shares) | 6 | 5 | 5 | 32 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 6 | 7 | 5 | 10 | 31 | |
| Short-term bank deposits | 15 | 23 | — | — | — | |
| Restricted cash | 422,000 | 254,000 | — | — | — | |
| Customer receivables | 236,000 | 34,000 | — | — | — | |
| Prepaid expenses and other current assets | 824,000 | 834,000 | 969,000 | 2 | 2 | |
| Total current assets | 22 | 31 | 41 | 58 | 67 | |
| Restricted bank deposits | 879,000 | 634,000 | 627,000 | 634,000 | — | |
| Severance pay fund | 610,000 | 470,000 | 439,000 | 661,000 | 664,000 | |
| Property and equipment, net | 2 | 688,000 | 688,000 | 739,000 | 1 | |
| Intangible assets, net | 3 | — | — | — | — | |
| Goodwill | 3 | — | — | — | — | |
| Operating lease right-of-use asset | 7 | 7 | 8 | 8 | 728,000 | |
| Other long-term assets | 447,000 | 70,000 | 1,000 | 14,000 | 7,000 | |
| Total long-term assets | 17 | 8 | 9 | 10 | 26 | |
| Total assets | 39 | 40 | 51 | 68 | 94 | |
| Trade payables | 866,000 | 964,000 | 2 | 2 | 3 | |
| Accrued expenses | 1 | 1 | 1 | 2 | 6 | |
| Operating lease liability | 659,000 | 559,000 | 627,000 | 619,000 | 634,000 | |
| Accrued vacation and recuperation | 859,000 | 702,000 | 873,000 | 1 | — | |
| Advances from customers | 148,000 | 43,000 | — | — | — | |
| Loan from the European Investment Bank, or EIB | 27 | — | — | — | — | |
| Other accounts payable | 1 | 963,000 | 1 | 2 | — | |
| Total current liabilities | 32 | 4 | 6 | 7 | 12 | |
| Accrued severance pay | 703,000 | 605,000 | 598,000 | 867,000 | 920,000 | |
| Operating lease liability | 6 | 5 | 6 | 7 | 100,000 | |
| Deferred tax liabilities | 415,000 | — | — | — | — | |
| Loan from EIB | — | 24 | — | — | — | |
| Total long-term liabilities | 7 | 30 | 30 | 29 | 25 | |
| COMMITMENTS AND CONTINGENCIES | — | — | — | — | — | |
| Common shares, $0.00001 par value per share: authorized: 37,500,000 as of June 30, 2025 and 2024; issued and outstanding: 7,893,767 and 5,408,212 shares as of June 30, 2025 and 2024, respectively | — | — | — | — | — | |
| Additional paid-in capital | 436 | 421 | 413 | 401 | 387 | |
| Accumulated deficit | −443 | −420 | −400 | −371 | −330 | |
| Total shareholders (deficit) equity | −7 | 96,000 | 13 | 30 | 57 | |
| Non-controlling interests | 6 | 5 | 2 | 2 | — | |
| Total equity (deficit) | −865,000 | 5 | 15 | 32 | 57 | |
| Total liabilities and equity | 39 | 40 | 51 | 68 | 94 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 316,000 | 253,000 | — | — | — | |
| Share-based compensation to employees, directors and non-employee consultants | 2 | 3 | 4 | 9 | 14 | |
| Decrease in fair value of warrant and pre-funded warrant liability | −556,000 | — | — | — | — | |
| Decrease (increase) in customer receivable | −202,000 | 76,000 | — | — | — | |
| Decrease (increase) in prepaid expenses and other current assets and other long-term assets | 1,000 | −44,000 | 768,000 | 93,000 | 303,000 | |
| Decrease in trade payables | −235,000 | −778,000 | −22,000 | −758,000 | 578,000 | |
| Increase (decrease) in other accounts payable, accrued vacation and recuperation, deferred tax liabilities and accrued expenses | 377,000 | −287,000 | −1 | −4 | 3 | |
| Increase in advances from customers | 105,000 | 36,000 | — | — | — | |
| Increase in operating lease right-of-use asset and liability, net | 834,000 | 285,000 | — | — | — | |
| Decrease (increase) in interest receivable on short-term deposits | 91,000 | 438,000 | −336,000 | −329,000 | −256,000 | |
| Effect of exchange rate changes on cash, cash equivalents, deposits and restricted cash | −1 | 253,000 | 831,000 | 3 | −618,000 | |
| Increase in short-term interest payable and exchange rate differences related to the EIB loan, net | 3 | 497,000 | 2 | −2 | 78,000 | |
| Decrease in accrued severance pay, net | −42,000 | −24,000 | −47,000 | −50,000 | 8,000 | |
| Net cash used for operating activities | −18 | −18 | −23 | −37 | −31 | |
| Purchase of property and equipment | −2 | −323,000 | −262,000 | −280,000 | −373,000 | |
| Proceeds from short-term deposits, net | 9 | 11 | 10 | — | — | |
| Cash related to Kokomodo Transaction (defined below) | 373,000 | — | — | — | — | |
| Net cash provided by investing activities | 8 | 11 | 10 | 12 | −7 | |
| Issuance of common shares, pre-funded warrants and warrants, net of issuance costs | 10 | 91,000 | 8 | — | 37 | |
| Issuance costs related to issuance of shares in Kokomodo Transaction (defined below) | −47,000 | — | — | — | — | |
| Issuance of Ever After Foods shares to non-controlling interests | — | 9 | — | — | — | |
| Net cash provided by financing activities | 10 | 9 | 8 | 8 | 61 | |
| EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | 177,000 | 11,000 | −22,000 | −3 | −126,000 | |
| Increase (decrease) in cash, cash equivalents, restricted cash and restricted bank deposits | −475,000 | 1 | −5 | −20 | 23 | |
| Purchase of property and equipment on credit | 90,000 | 4,000 | — | — | — | |
| Kokomodo Transaction (defined below) | 5 | — | — | — | — | |
| Lease liabilities arising from obtaining right-of-use assets | 1 | 82,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro